Literature DB >> 21557880

Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults.

Martin Cohen1, Paul E Rasser1, Greg Peck2, Vaughan J Carr1, Philip B Ward3, Paul M Thompson4, Patrick Johnston5, Amanda Baker1, Ulrich Schall1.   

Abstract

Epidemiological data link adolescent cannabis use to psychosis and schizophrenia, but its contribution to schizophrenia neuropathology remains controversial. First-episode schizophrenia (FES) patients show regional cerebral grey- and white-matter changes as well as a distinct pattern of regional grey-matter loss in the vermis of the cerebellum. The cerebellum possesses a high density of cannabinoid type 1 receptors involved in the neuronal diversification of the developing brain. Cannabis abuse may interfere with this process during adolescent brain maturation leading to 'schizophrenia-like' cerebellar pathology. Magnetic resonance imaging and cortical pattern matching techniques were used to investigate cerebellar grey and white matter in FES patients with and without a history of cannabis use and non-psychiatric cannabis users. In the latter group we found lifetime dose-dependent regional reduction of grey matter in the right cerebellar lobules and a tendency for more profound grey-matter reduction in lobule III with younger age at onset of cannabis use. The overall regional grey-matter differences in cannabis users were within the normal variability of grey-matter distribution. By contrast, FES subjects had lower total cerebellar grey-matter:total cerebellar volume ratio and marked grey-matter loss in the vermis, pedunculi, flocculi and lobules compared to pair-wise matched healthy control subjects. This pattern and degree of grey-matter loss did not differ from age-matched FES subjects with comorbid cannabis use. Our findings indicate small dose-dependent effects of juvenile cannabis use on cerebellar neuropathology but no evidence of an additional effect of cannabis use on FES cerebellar grey-matter pathology.

Entities:  

Mesh:

Year:  2011        PMID: 21557880     DOI: 10.1017/S146114571100068X

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  21 in total

1.  Cannabis use in youth is associated with limited alterations in brain structure.

Authors:  J Cobb Scott; Adon F G Rosen; Tyler M Moore; David R Roalf; Theodore D Satterthwaite; Monica E Calkins; Kosha Ruparel; Raquel E Gur; Ruben C Gur
Journal:  Neuropsychopharmacology       Date:  2019-02-19       Impact factor: 7.853

Review 2.  Neuroimaging Studies in Patients With Mental Disorder and Co-occurring Substance Use Disorder: Summary of Findings.

Authors:  Kaloyan Rumenov Stoychev
Journal:  Front Psychiatry       Date:  2019-10-23       Impact factor: 4.157

3.  Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling.

Authors:  Miriam Fishbein; Sahar Gov; Fadi Assaf; Mikhal Gafni; Ora Keren; Yosef Sarne
Journal:  Exp Brain Res       Date:  2012-07-22       Impact factor: 1.972

4.  Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders.

Authors:  Laura Koenders; Marise W J Machielsen; F J van der Meer; Angelique C M van Gasselt; Carin J Meijer; Wim van den Brink; Maarten W J Koeter; Matthan W A Caan; Janna Cousijn; Anouk den Braber; Dennis van 't Ent; Maaike M Rive; Aart H Schene; Elsmarieke van de Giessen; Chaim Huyser; Bart P de Kwaasteniet; Dick J Veltman; Lieuwe de Haan
Journal:  J Psychiatry Neurosci       Date:  2015-05       Impact factor: 6.186

Review 5.  A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis.

Authors:  Justin Davis; Harris Eyre; Felice N Jacka; Seetal Dodd; Olivia Dean; Sarah McEwen; Monojit Debnath; John McGrath; Michael Maes; Paul Amminger; Patrick D McGorry; Christos Pantelis; Michael Berk
Journal:  Neurosci Biobehav Rev       Date:  2016-04-09       Impact factor: 8.989

6.  MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse.

Authors:  O E Onwuameze; K W Nam; E A Epping; T H Wassink; S Ziebell; N C Andreasen; B-C Ho
Journal:  Psychol Med       Date:  2012-07-31       Impact factor: 7.723

7.  Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex.

Authors:  Leonora E Long; Jonna Lind; Maree Webster; Cynthia Shannon Weickert
Journal:  BMC Neurosci       Date:  2012-07-24       Impact factor: 3.288

Review 8.  Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies.

Authors:  Charlotte Rapp; Hilal Bugra; Anita Riecher-Rössler; Corinne Tamagni; Stefan Borgwardt
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

9.  An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use.

Authors:  Else-Marie Løberg; Merethe Nygård; Jan Øystein Berle; Erik Johnsen; Rune A Kroken; Hugo A Jørgensen; Kenneth Hugdahl
Journal:  Front Psychiatry       Date:  2012-10-30       Impact factor: 4.157

Review 10.  Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence.

Authors:  Berend Malchow; Alkomiet Hasan; Paolo Fusar-Poli; Andrea Schmitt; Peter Falkai; Thomas Wobrock
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-08-21       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.